Niktimvo marks the first FDA-approved therapy targeting CSF-1R to address inflammation and fibrosis in chronic graft-versus-host disease.
FDA Approves Incyte and Syndax’s Niktimvo for Chronic Graft-Versus-Host Disease in 9 and 22 mg Vial Sizes
You May Also Like
Where can I buy Tobacco-Free Nicotine products?
February 27, 2025
Ozempic 用於什麼？
February 26, 2025
Global Launch Strategies in the Current Political Climate
February 19, 2025
+ There are no comments
Add yours